Related Experiment Videos
Serum collagenase activity in chronic liver diseases
Y Murawaki1, H Kawasaki, H Burkhardt
1Second Department of Internal Medicine, Tottori University School of Medicine, Yonago, Japan.
Pathology, Research and Practice
|October 1, 1994
Summary
Serum collagenase activity decreases in chronic liver disease due to increased Tissue Inhibitor of Metallo-Proteinases (TIMP), suggesting it may not accurately reflect hepatic collagenase levels.
Area of Science:
- Biochemistry
- Hepatology
- Medical Research
Background:
- Collagenase activity is crucial in liver fibrogenesis.
- Assessing hepatic collagenase via serum activity is a potential diagnostic approach.
- Inhibitors like TIMP can affect enzyme activity measurements.
Purpose of the Study:
- To determine if serum collagenase activity correlates with hepatic collagenase in fibrotic liver disease.
- To investigate the role of TIMP in modulating serum collagenase activity in liver disease patients.
Main Methods:
- Measured serum collagenase activity in 67 chronic liver disease patients and 26 controls.
- Reactivated serum collagenase using 3 M KSCN and 1 mM aminophenylmercuric acetate.
- Quantified serum TIMP concentration using immunoassays.
Main Results:
- Serum collagenase activity was significantly lower in patients with chronic persistent hepatitis, chronic active hepatitis, liver cirrhosis, and hepatocellular carcinoma compared to controls.
- Serum TIMP concentration was elevated in liver disease patients and inversely correlated with serum collagenase activity.
Conclusions:
- Serum collagenase activity in the assay is influenced by TIMP.
- Serum collagenase activity may not accurately reflect hepatic collagenase levels in chronic liver disease.
- Further research is needed to develop reliable biomarkers for hepatic collagenase in fibrotic liver disease.